Citations

Clear

6055 citation(s) found for "Wu, Peter".

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer
Bryant, John Michael, Sandoval, Maria, Putney, Ryan, Trivedi, Purvish , Katende, Esther N. , Fink, Angelina, Naqvi, Syeda Mahrukh, Kim, Youngchul, Yin, Vivian, Zhang, Jingsong, Park, J Y, Serna, Amparo, Lam, Nghi, Pow-Sang, J., Poch, Michael, Li, Roger, Manley, Brandon J, Naghavi, Arash, Torres-Roca, Javier, Grass, G Daniel, Kim, S, Latifi, Kujtim, Hunt, Dylan, Johnstone, Peter, Dhillon, Jasreman, Rodriguez, Paulo C, Jain, Rohit, Fernandez, Daniel C. , Yamoah, Kosj , Bryant, John Michael, Sandoval, Maria L., Putney, Ryan M. , Zhang, Jingsong , Serna, Amparo , Lam, Nghi B. , Poch, Michael , Manley, Brandon J, Naghavi, A.O. , Grass, G. Daniel , Latifi, Kujtim , Dhillon, Jasreman

Mayo Clinic

Journal for ImmunoTherapy of Cancer | May 4, 2026 | Volume: 14 | Issue: 5 | Pages: e013906

10.1136/jitc-2025-013906 | PMID 42082271 Get It

Background Grade group 5 (GG5) prostate cancer (PCa) carries a less favorable prognosis after standard-of-care (SOC) therapy, necessitating novel therapeutic approaches. High-dose rate brachytherapy (HDRBT) and androgen deprivation therapy (ADT) may modulate immune response in GG5 PCa, particularly in tumors with increased immune content. This study evaluated whether the addition of nivolumab to SOC was associated with improved disease control in patients with high-volume GG5 PCa, including those with oligometastatic disease. Methods In this non-randomized phase II trial, 31 patients with localized or oligometastatic GG5 PCa and >30% positive biopsy cores were evaluated between September 2018 and April 2021. Patients received four doses of nivolumab (240 mg every 2 weeks) beginning 4 weeks prior to HDRBT, alongside ADT, HDRBT, and external beam radiation. The primary endpoint was to evaluate whether the 2-year freedom from biochemical recurrence (FFBR) rate would exceed a prespecified historical control rate of 75%. Results Among the 31 patients, the median follow-up was 38.8 months (IQR 31.0–46.5 months). The addition of nivolumab to SOC RT with ADT was associated with a 2-year FFBR rate of 90.3% (95% CI 74.3% to 98.0%) (median FFBR not reached), exceeding the prespecified historical control rate of 75% (one-sided p value from binomial test=0.024). Definitive and probable nivolumab-related toxicity included 6.3% acute grade 2 and 6.3% acute grade 3 adverse events (AEs), with no grade 4+ AEs observed. A higher Decipher immunosuppression score at diagnosis correlated with early pathologic response (p=0.005) and was independently associated with time to metastatic failure (p=0.044). Conclusions Nivolumab combined with SOC was associated with encouraging FFBR in this high-risk GG5 PCa population and may represent a promising therapeutic intensification strategy. The Decipher immunosuppression score may serve as a predictive biomarker for response. These findings warrant further investigation in randomized trials.
Decoding RELA-Related Disease: A Spectrum of Immune Dysregulation in a Large Global Cohort
Dileepan, Gayathri , Basu, PhD Amrita, Murray, MD Elizabeth, D’Astous-Gauthier, Katherine , Lawrence, Monica G. , Maltz, Ross, Paquin, Maxime, Saca, MD Luis F., Taxter, Alysha J. , Towers, Victoria, Wonnaparhown, Alex , Akoghlanian, Shoghik , PhD, Eric Allenspach, MD,, Alsulami, Saleh , Alsuweiti, Motasem O. , Ardalan, Kaveh , CHAN, R P, MSCE, Joyce Chang, MD,, Efron, Adi , Igel, Dr. med Lina, Nigrovic, Peter, Padem, Nurcicek , Rosenwasser, Natalie , Sanchez-Manubens, PhD Judith, Skrie, Victor, Zheng, S , Guo, Lily, D(ABMLI), Roshini Abraham, PhD,, Basu, Amrita, Murray, Elizabeth T., Chapdelaine, Hugo , Maltz, Ross , Peng, Xiao P. , Saca, Luis, Zimmerman, Ofer , Allenspach, Eric J , Broderick, Lori , Cebecauerová, Dita , Dedeoğlu, Fatma , Igel, Lina, Naesens, Leslie , Nigrovic, Peter Andrija , Ombrello, Amanda K. , Sivaraman, Vidya

Mayo Clinic

Journal of Human Immunity | May 1, 2026 | Volume: 2 | Issue: CIS2026 | Pages: No page available

10.70962/cis2026abstract.7 Get It

RELA-related disease is a rare, autosomal-dominant condition presenting with immune dysregulation and immunodeficiency. RELA encodes the p65 subunit, a component of the canonical NFκB pathway. The underlying pathogenesis, at least in part, involves impaired NFκB activation, increased susceptibility to TNFα-induced apoptosis, and hyperinflammation. To date, only a modest number of cases have been documented worldwide, and the full clinical and functional spectrum of disease remains incompletely defined. This study represents a large global cohort identified with RELA variants, comprising 40 patients from 30 institutions, expanding our previous report of a single large kindred (1). The clinical spectrum includes arthritis, mucocutaneous ulcers, uveitis, dermatitis, irritable bowel disease, recurrent infections, lymphopenia, hypogammaglobulinemia, recurrent fevers, and susceptibility to neoplasia. The patients represent 36 kindreds with 28 unique RELA variants, of which 15 are missense, 7 nonsense, and 6 frameshift variants. Fifteen are in the Rel homology domain, 7 in the transcriptional activation domain, and 6 in the C-terminal region proximal to TAD (Fig. 1). Functional studies assessed the canonical NFκB pathway in 27% of the cohort (n = 11; healthy controls = 40). Patient peripheral blood mononuclear cells (PBMCs) were used to quantify total and phosphorylated p65 (ph-p65, Ser529) by flow cytometry after stimulation with PMA (100 ng/ml) and ionomycin (1 uM). In 8 patients, we assessed the kinetics of IκBα degradation, required for p65 phosphorylation and nuclear translocation of p65/p50. All patients tested had decreased total p65, while 64% had decreased ph-p65 with altered phosphorylation kinetics. Nearly 45% had impaired IκBα degradation. One patient (P4) demonstrated increased IκBα degradation and ph-p65, while a related proband (P1) had decreased ph-p65. Additionally, P4 did not have the same mucocutaneous clinical phenotype as P1 despite sharing the same RELA variant. This could reflect the effect of other genetic modifiers, epigenetic, environmental, or stochastic variations, which could lead to variable expressivity and/or incomplete penetrance. All patients appeared to have haploinsufficiency, as none had normal levels of p65. This study expands the clinical and genetic spectrum of RELA-related disease and provides mechanistic insights into the impact of these variants on p65 phosphorylation and downstream function, resulting in variable expressivity. Figure 1. RelA protein structure. Represents unique variant locations and categories, key domains, and phosphorylation sites. Source: UniProt. Adapted from (2). BioRender.
Abstract WE404: Trends in Survival after Atrial Fibrillation in a Midwestern Community
Manemann, Sheila, Salama, Peter, Tordsen, Walker, Killian, Jill, Vaughan, Lisa, Gersh, Bernard, Siontis, Konstantinos, Noseworthy, Peter, DeSimone, Christopher, Deshmukh, Abhishek, Chamberlain, Alanna, Manemann, Sheila M., Salama, Peter, Tordsen, Walker, Killian, Jill M. , Vaughan, Lisa E. , Gersh, Bernard, Noseworthy, Peter, DeSimone, Christopher V. , Deshmukh, Abhishek , Chamberlain, Alanna M.

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.we404 Get It

Background: Contemporary data on trends in survival after incident atrial fibrillation (AF) are limited. Methods: Residents of a 27-county area in southern Minnesota and western Wisconsin with new-onset atrial fibrillation or atrial flutter between 2013 and 2023 were identified. An electronic algorithm requiring 1 inpatient code or 2 outpatient codes separated by >7 days but within 1 year was used to define AF. Patients were followed for all-cause mortality through March 31, 2025. Standardized mortality ratios of observed versus expected survival were calculated, and time trends in survival were examined using Cox regression adjusting for demographics, cardiovascular risk factors, comorbid conditions, and area-level measures of socioeconomic status and rurality. Results: There were 44,930 individuals identified with incident AF from 2013-2023 (56.4% male; mean (SD) age 72.8 (13.5) years; 95.8% were non-Hispanic white). Within the first 90 days, the risk of all-cause mortality was greatly elevated compared with individuals of a similar age and sex distribution in the general population (standardized mortality ratios 12.6, 95% CI, 12.1-13.0 and 3.8, 95% CI, 3.6-4.0 for the first 30 days and 31 to 90 days after diagnosis, respectively). This excess risk was observed for all age groups but was greatest in the youngest age group (standardized mortality ratios among 18-64 year olds for the first 30 days: 49.9, 95% CI, 44.6-55.7 and 31 to 90 days: 11.1, 95% CI: 9.4-13.1; Figure ). In the youngest age group, the excess risk persists through 5 years post AF, however, in the oldest age group the excess risk only persisted through 1 year. Survival within the first 90 days improved over the study period (adjusted hazard ratio [aHR], 0.88; 95% CI, 0.79-0.99 for 2023 vs 2013); likewise, among 90-day survivors, survival improved between 2013 and 2023 (aHR,0.82; 95% CI, 0.76-0.88). These trends were driven by improvements in the younger age groups, particularly for death among 90-day survivors (aHR for 18-64 years, 0.66, 95% CI, 0.52-0.83; 65-74 years: 0.77, 95% CI: 0.65-0.90; 75-84 years, 0.84, 95% CI: 0.75-0.95; 85+ years, 0.99, 95% CI: 0.98-1.01). Conclusion: In a Midwestern community, the excess risk of death is high within the first 90 days after incident AF. Furthermore, survival after AF has improved between 2013 and 2023, with the improvement greatest in younger age groups.
Percutaneous spinal stimulation to enhance gait and alleviate functional impairments in multiple sclerosis: A pilot study
Jahanian, Omid , Asp, Anders J., Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Hogen, Cecilia A., Mills, Candee J. , Thoreson, Andrew R. , Grahn, Peter J. , Fernandez, Katrina A, Tobin, W Oliver , Fernandez, K A , Jahanian, Omid , Asp, Anders J., Solinsky, Ryan , Kaufman, Kenton R. , Zhao, Kristin D. , Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal – Experimental, Translational and Clinical | April 29, 2026 | Volume: 12 | Issue: 2 | Pages: No page available

10.1177/20552173261432301 | PMID 42112095 Get It

Objective To evaluate the feasibility and potential efficacy of percutaneous spinal stimulation (epidural stimulation, ES) combined with task-specific training to reduce spasticity and improve gait and balance in individuals with progressive multiple sclerosis (MS). Methods Two men with progressive MS (EDSS 6.5) underwent ES lead implantation targeting the lower spinal cord, followed by one month of rehabilitation involving 12 ES-assisted training sessions. Assessments included instrumented gait analysis, Modified Ashworth Scale (MAS), pendulum test, and static balance testing performed at baseline, and at end of the study with ES-Off and ES-On conditions. Results Participant 1, with spastic hemiparetic gait, demonstrated improved lower extremity joint kinematics and muscle activation during gait, reduced knee extensor spasticity, and enhanced functional movement patterns with ES-On. Participant 2, with significant paraparesis and minimal spasticity, showed limited gait changes but experienced marked improvements in static balance, particularly under eyes-closed conditions. No adverse events were reported. Conclusion This pilot study demonstrates the feasibility and tolerability of ES paired with task-specific training in progressive MS. Participant-specific responses were observed, including improvements in gait kinematics, neuromuscular activation, spasticity, or balance; however, spatiotemporal gait parameters did not improve. These preliminary findings highlight response heterogeneity and the need for individualized ES parameter tuning. Trial registry name and URL: https://clinicaltrials.gov/study/NCT06019611
Standardizing Data Collection in Normothermic Regional Perfusion in the United States
Aufhauser, David D. , Philip, Jenny L, Sellers, Marty , Croome, Kris P, Bababekov, Yanik J. , Paci, P., Montenovo, Martin I. , Merani, Shaheed , Abt, Peter L. , Nydam, Trevor, Nassar, Ahmed , Sellers, Marty T. , Paci, Philippe , Mao, Shennen A. , Nydam, Trevor L. , Botha, Jean Frederick , Wall, Anji , Brubaker, Aleah L.

Mayo Clinic

Annals of Surgery | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007078 | PMID 42050633 Get It

Phase II Trial of Encapsulated Rapamycin to Reduce Polyp Burden Associated with Familial Adenomatous Polyposis
Broderick, Joseph C , Samadder, N. Jewel , Stoffel, Elena , Fang, John C. , Stanich, Peter P. , Wise, Paul , Wright, Randy , Clifton, Travis, Peoples, George E. , Broderick, Joseph , Stoffel, Elena M. , Clifton, Guy T. , Wise, Paul E. , Samadder, N Jewel , Clifton, Guy T , Peoples, George , Burke, Carol A , Broderick, Joseph C, Burke, Carol A.

Mayo Clinic

Clinical Cancer Research | April 28, 2026 | Volume: 32 | Issue: 15 | Pages: 3146-3156

10.1158/1078-0432.ccr-25-4126 | PMID 42048421 Get It

Abstract Purpose: Familial adenomatous polyposis (FAP) confers a significant risk of colorectal/duodenal cancer. Encapsulated rapamycin (eRapa) has demonstrated promise as FAP chemoprevention in early clinical studies. Patients and Methods: Thirty patients with FAP enrolled to three dosing regimens of eRapa (0.5 mg): cohort 1—every other day, cohort 2—daily every other week, or cohort 3—daily. The primary endpoints were safety/tolerability, pharmacokinetics, and percentage change from baseline (PCFB) in colorectal polyp burden (CPB) at 6 months. Secondary endpoints included PCFB total (TPB) and duodenal (DPB) polyp burden and change in International Society for Gastrointestinal Hereditary Tumors stage and Spigelman score at 6 and 12 months. Results: Twenty nine of thirty patients (97%) completed the 12-month study with predictable bioavailability. Low-grade adverse events were frequent but most pronounced in daily dosing. Two patients discontinued treatment related to toxicity. Cohort 1 had the largest decrease median PCFB CPB, DPB, and TPB at 6 months: −39.4 % (IQR, 108.9; P = 0.28), −33.33 % (IQR, 90; P = 0.04), and −38.6 % (IQR, 88.5; P = 0.26), respectively. At 12 months, cohort 2 had the largest decrease median PCFB CPB and TPB: −29.3 % (IQR, 67.6; P = 0.37) and −26.3 % (IQR, 49.5; P = 0.29), respectively. Intermittent dosing cohorts (1 and 2) reduced DPB at 6 months (P = 0.04) and improved TPB at 12 months (P = 0.05) compared with daily dosing. Conclusions: eRapa was safe, tolerable, and showed preliminary efficacy for FAP chemoprevention. The 0.5 mg daily every-other-week schedule will be evaluated in an upcoming phase III trial.
Presacral tumours: international consensus on diagnosis and management
Perry, William R G, Brown, KF, Burns, Elaine, Frizelle, Frank, Glover, Thomas , Glyn, Tamara , Heriot, Alexander, Merchea, Amit , Quyn, Aaron, Sagar, P., Thomas, Gregory, Tiernan, Jim , Turner, Gregory A., Warrier, Satish, Wood, Verity, Group, the Presacral Tumour Working, Cerkaukaite, Dovile, Khan, Ayman , Koneru, S R, Vu, J, Jenkins, John T. , Dozois, E, Heriot, Alexander G. , Perry, William , Perry, William R , Heriot, Alexander , Merchea, Amit , Sagar, Peter , Solomon, Michael J , Burns, Elaine Marie , Denost, Quentin , Graham, Rondell P. , Solomon, Michael J. , Turner, Gregory A, Wood, Verity , Koneru, Sireesha, Litchinko, Alexis , Dozois, Eric J.

Mayo Clinic

British Journal of Surgery | April 28, 2026 | Volume: 113 | Issue: 5 | Pages: No page available

10.1093/bjs/znag053 | PMID 42049258 Get It

Abstract Background Presacral tumours are rare and heterogeneous lesions arising within a complex anatomical space, resulting in variability in diagnosis and management. Increasing incidental detection and evolving surgical and oncological strategies have highlighted the need for contemporary guidance. The aim of this study was to establish an international expert consensus on the optimal diagnosis and management of presacral tumours. Methods An international panel of colorectal surgeons from high-volume units was convened. Evidence- and practice-based statements were developed after domain-based literature reviews and refined through five online and two in-person meetings. Consensus was achieved using a modified Delphi process with anonymous voting. Results In total, 16 colorectal surgeons participated in the study. Ten domains were identified resulting in the development of 22 statements based on expert opinion and retrospective studies. After two rounds, unanimous (100%) agreement was achieved for all statements. High-resolution MRI with structured synoptic reporting is endorsed as central to risk stratification. Selective image-guided transperineal or parasacral biopsy is recommended for high-risk lesions where histology would alter management. Complete surgical resection is defined as the operative goal, with approach tailored to tumour biology and anatomy; minimally invasive surgery is considered appropriate in selected cases. Non-operative surveillance is supported for carefully selected asymptomatic, low-risk cystic lesions. Postoperative surveillance is recommended in a risk-adapted manner according to histopathology and margin status. Conclusion This international consensus provides a pragmatic, risk-stratified framework for the multidisciplinary diagnosis and management of presacral tumours. These recommendations aim to reduce practice variation, support decision-making in specialized centres, and inform future prospective collaborative research.
Status Epilepticus After Carotid Endarterectomy: An Illustrative Case of Cerebral Hyperperfusion Syndrome
Reuter, Peter , Sailor, Mandy, Hutchinson, Valeria Ariza , Ariza Hutchinson, Valeria , Reuter, Peter J.

Mayo Clinic

Stroke | April 27, 2026 | Volume: 57 | Issue: 5 | Pages: No page available

10.1161/strokeaha.125.053882 | PMID 42044229 Get It

Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus
Meletti, Stefano, Hanin, Aurelie, Bedin, Roberta , Burani, Margherita , Taruffi, Lisa , Urbano, Teresa, d’Achille, Fabio, Malerba, Mara, Basha, Maysaa M., Eschbach, Krista, Farias-Moeller, Raquel, Gerard, Elisabeth E., Gofton, Teneille, Gopaul, Margaret T., Haider, Hiba A. , Hantus, Stephen , Herman, Susan, Kang, Peter, Kandula, Padmaja , Taraschenko, Olga , Wainwright, Mark, Zhou, Daniel J., Lattanzi, Simona, Navarro, Vincent, Hirsch, Lawrence J., Meletti, Stefano , Haider, Hiba A , Hanin, Aurélie , Giovannini, Giada , Orlandi, Niccolò , Urbano, Teresa , Malerba, Mara, Basha, Maysaa , Foreman, Brandon , Farias‐Moeller, Raquel , Gaspard, Nicolas , Gofton, Teneille , Gopaul, Margaret , Day, Gregory S. , Steriade, Claude , Struck, Aaron F. , Wainwright, Mark S. , Yoo, Ji Yeoun , Lattanzi, Simona , Navarro, Vincent , Hirsch, Lawrence J.

Mayo Clinic

JAMA Neurology | April 27, 2026 | Volume: 83 | Issue: 6 | Pages: 563

10.1001/jamaneurol.2026.0865 | PMID 42043830 Get It

Importance Seizure-induced brain injury is central to the treatment urgency of new-onset refractory status epilepticus (NORSE). Identifying biomarkers that reflect ongoing neuronal damage could inform therapeutic timing and improve outcomes. Objective To quantify acute brain injury in patients with cryptogenic NORSE (cNORSE), etiology-defined status epilepticus (eSE), and chronic epilepsy. Design, Setting, and Participants This was an international cross-sectional study conducted between 2013 and 2025. Patients were enrolled at 36 hospitals in the US, 2 in Canada, and 1 in Italy, France, and Belgium. Patients with cNORSE and eSE for which biological samples were obtained during ongoing seizure activity were enrolled in the study. Comparison groups without status epilepticus comprised individuals with chronic epilepsy and healthy participants. None were excluded. Exposures Neurofilament light chain (NfL) and S100-beta (S100B) protein concentrations in serum and cerebrospinal fluid (CSF). Main Outcomes and Measures Degree of neuronal and glial damage, indexed by NfL and S100B levels, and their association with short-term functional outcomes. Results A total of 78 patients with cNORSE (mean [95% CI] age, 37 [30-41] years; 44 female [56%]) and 2 independent cohorts of 211 patients (mean [95% CI] age, 69 [66-71] years; 128 female [61%]) and 73 patients (mean [95% CI] age, 56 [45-65] years; 39 male [53%]) with eSE were included. NfL concentrations were markedly elevated in cNORSE—approximately 10-fold higher in CSF and 4-fold higher in serum—compared with the eSE cohorts (CSF: median [IQR], 6408 [1503-22 963] pg/mL compared with 694 [219-2389] pg/mL; serum: median [IQR], 231 [99-855] pg/mL compared with 55 [20-135] pg/mL; P <.001). Serum NfL levels were nearly 20-fold higher in cNORSE than in the cohort with epilepsy and in healthy controls (median [IQR], 11 [7-19 ] and 7 [5-14 ] pg/mL, respectively). Serum and CSF NfL levels were strongly correlated (Spearman ρ = 0.75; P < .001) and rose sharply between week 1 (median [IQR], 101 [51-137] pg/mL), week 2 (median [IQR], 197 [117-324] pg/mL), and week 3 (median [IQR], 598 [163-1000] pg/mL) after onset ( P < .001). In contrast, S100B concentrations did not differ between groups and showed no consistent temporal pattern. NfL discriminated cNORSE from eSE (area under the receiver operating characteristic curve [AUROC], 0.79; 95% CI, 0.68-0.90) and from cohorts without status epilepticus (AUROC, 0.99; 95% CI, 0.78-1.00). Higher serum NfL was independently associated with poor functional outcome at discharge (Glasgow Outcome Scale extended score, 1-4; odds ratio, 1.01; 95% CI, 1.00-1.03; P = .03). Conclusions and Relevance Results of this cross-sectional study suggest that acute neuroaxonal injury, as reflected by elevated NfL levels, was substantially greater in cNORSE than in the cohorts with eSE and in controls without status epilepticus. The rapid early rise in NfL highlights a narrow therapeutic window, emphasizing the need for prompt, effective, and potentially neuroprotective interventions in cNORSE.
First-in-Human Clinical Experience With Focal Pulsed Field and Radiofrequency Dual-Modality Ablation for Treatment Refractory Left Ventricular Summit PVCs
Patil, Shivaraj, Liu, Xiaoke Ken, Siontis, Konstantinos C. , Prasitlumkum, Narut , Asirvatham, S, Cha, Yong‐Mei , Munoz, Freddy Del‐Carpio , Deshmukh, Abhishek , DeSimone, Christopher V. , Friedman, Paul A. , Madhavan, Malini , Mulpuru, S K, Munger, Thomas, Nguyen, Duy T. , Tan, N, Sugrue, Alan , Killu, Ammar M. , Asirvatham, Samuel J. , Liu, Xiaoke , Asirvatham, Samuel J , Del-Carpio Munoz, Freddy , Deshmukh, Abhishek J , Ezzeddine, Fatima , Friedman, Paul A , Kowlgi, Narayan G , Madhavan, Malini , Mulpuru, Siva K , Nguyen, Duy, Noseworthy, Peter A , Tan, Nicholas , Sugrue, Alan , Kapa, Suraj , Killu, Ammar M , DeSimone, Christopher V , Prasitlumkum, Narut , Ezzeddine, Fatima M. , Kowlgi, Gurukripa N. , Mulpuru, Siva K. , Munger, Thomas M., Noseworthy, Peter A. , Kapa, Suraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 24, 2026 | Volume: 19 | Issue: 6 | Pages: No page available

10.1161/circep.126.014942 | PMID 42030455 Get It

BACKGROUND: Radiofrequency (RF) ablation of premature ventricular complexes (PVCs) originating from the left ventricular summit may be unsuccessful, highlighting the need for alternative approaches. We aimed to assess the efficacy and safety of a novel dual-modality focal catheter in treating left ventricular summit PVCs in patients who had failed previous RF ablation. METHODS: Patients were prospectively enrolled and underwent a redo ablation procedure using an irrigated, contact-force sensing, dual-modality focal catheter (TactiFlex Duo, Abbott) under compassionate use indication. The ablation strategy, including the choice of energy modality (monopolar pulsed field [PF], RF, or both), was left to the operator’s discretion. Safety assessments included serial biomarkers, renal function, and CMR within 36 hours. Efficacy was defined as ≥80% reduction in PVC burden with symptom resolution at 3-month follow-up. RESULTS: Six consecutive patients (4 men; mean age, 53.8±15 years) with symptomatic left ventricular summit PVCs and a prior failed RF ablation (range, 1–2) were prospectively enrolled. All PVCs had an inferior axis, with a left bundle V1 morphology observed in 4 of 6 cases (mean burden, 30.1±5.3%). Acute suppression of PVCs was achieved in all cases. Acute suppression with a single PF application in the great cardiac vein-anterior interventricular vein occurred in 2 patients, while 3 patients required additional RF, PF, or combined RF+PF applications at adjacent sites. One patient with an inaccessible great cardiac vein-anterior interventricular vein was successfully treated in the left ventricular outflow tract with RF+PF application. Transient, reversible left anterior descending vasospasm was observed during PF delivery in 2 of 5 cases that underwent PF application adjacent to a coronary artery, despite pretreatment with intracoronary nitroglycerin without ECG or hemodynamic sequelae. All patients had durable suppression of PVCs at follow-up. CONCLUSIONS: In its first human application, dual-modality ablation was feasible and effective for refractory left ventricular summit PVCs. Transient coronary vasospasm occurred, though it was reversible and without acute clinical consequences.